Five papers that piqued our interest...
Luke Turner, Michael Schubert, James Strachan, Stephanie Sutton | | Quick Read
Investigational drug HU-308, which acts on CB2 receptors in the brain, lessened involuntary movements (dyskinesia) – a common side effect of drug treatment for Parkinson’s disease – in a mouse model (1).
We already know that over one-fifth of CBD products for health and wellness contain THC not listed on the label (2). A new study now reports that two out of six participants tested positive for THC after vaping CBDpredominant cannabis just once – a combination that could spell trouble for users undergoing drug testing (3).
Read the full article now
Log in or register to read this article in full and gain access to The Cannabis Scientist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Cannabis Scientist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.